Search results
Results From The WOW.Com Content Network
The world's largest drugmaker's profit tumbled 19 percent, although it slightly exceeded analysts' estimates. Revenue was largely impacted by unfavorable Pfizer tops estimates, but challenges remain
Pfizer's (PFE) fourth-quarter earnings and sales beat estimates. Its forecast for 2019 falls short of expectations. Stock dips 2% in pre-market trading.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Investors fled Pfizer last year as pandemic worries declined and billions of dollars in COVID-19 vaccine and treatment sales disappeared. Pfizer posts surprise 4th quarter profit, but key products ...
Pfizer (PFE) performs better than the industry in 2018 and looks well poised to keep the positive momentum alive in 2019.
However, on May 25 of the same year, Guidant reported 26 cases of implantable defibrillator failure, including a death. Johnson & Johnson announced the possibility of them pulling out from the deal, Guidant then sued Johnson & Johnson in an attempt to enforce the acquisition.
Pfizer William C. Gruber is an American physician-scientist , pediatrician, and business executive. He is the senior vice president of Pfizer vaccine clinical research and development.
Elise Amendola/AP Pfizer reported lower-than-expected quarterly earnings and revenue, and the largest U.S. drugmaker trimmed its full-year profit outlook, sending its shares down 3 percent. The ...